Prediction of response to neoadjuvant hormonal therapy (NAHT) using upfront oncotype Dx recurrence score (RS): Results from the SAFIA phase III trial von Al-Saleh, Khalid A, Bounedjar, Adda, Oukkal, Mohammed, Mahfouf, Hasen, Bouzid, Kamel, Bensalem, Assia, Fillali, Prof Taha, Larbaoui, Blaha, Kandil, Alaa, Alfoheidi, Meteb, Errihani, Hassan, Ghosn, Marwan, Abdulaziz, Nashwa A, Dabouz, Farida, Bahadoor, Mohun Ranvir K., El Zawahry, Heba Mohamed, Kullab, Sherif A, Nabholtz, Jean-Marc A.

Volltext